Randomized Phase III Trial of dd-MVAC, or GC as Perioperative Chemotherapy for Pts with MIBC. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses #VisualAbstract buff.ly/2YNCZpa

A new chapter for bladder cancer patients with a new class of drug. Enfortmab vedotin extending overall survival and progression free survival in randomised trials post IO and chemo. Both clinically meaningful - details in press release. #esmo20 . astellas.com/us/news/5176

Presidential symposium #ESMO20 Phase 3 CheckMate9ER study n= 651 shows first-line CaboNivo vs sunitinib improves PFS (16.6 vs 8.3m), OS (40% decrease risk of death) & ORR (55.7 vs 27.1%). Benefit in all IMDC risks. CaboNivo has potential as 1L tx for #RCC pts ESMO - Eur. Oncology Toni Choueiri, MD

November 2020 Issue Orsi Consensus Meeting on European Robotic Training (OCERT): Results from the First Multispecialty Consensus Meeting on Training in Robot-assisted Surgery buff.ly/2HLxbUa Editorial: buff.ly/2SnSDVi

There is growing evidence supporting single and combo neoadjuvant immune therapy in bladder cancer. This includes pCR and relapse free survival endpoints. Neoadjuvant approaches have theoretical biological advantages over adjuvant therapy . euoncology.europeanurology.com/article/S2588-…

I think that diversity in the panels of scientific meetings should be on top of the list of all the organizing committees. Don’t take the easy way ! European Association of Urology (EAU) ESMO - Eur. Oncology ESTRO Andrea Urzúa Assler Maria J. Ribal Stacy Loeb, MD Derya Tilki, MD Nikita Bhatt Renu Eapen Sima Porten Karen Fransis

Best of 2020 Visual Abstracts 9th Place The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis buff.ly/3cbTVuA

Best of 2020 Visual Abstracts 4th Place #VisualAbstract Randomized Phase III Trial of ddMVAC, and Cis, or Gem/Cis as Perioperative Chemotherapy for Pts with MIBC. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

It's cool how accurate sub-division of Luminal-like UC mirrors variant histology. Micropapillary=LumU, p63 - Nested=Lum-P, p63 + Nice work ⤵️

Our faculty can't wat to see you at #ERUS21